8 results about "Normal pregnancy" patented technology

The invention discloses a urine glycosylation protein marker for early auxiliary diagnosis of preeclampsia and application of the urine glycosylation protein marker. The invention discloses a urine glycosylation protein marker for early auxiliary diagnosis of preeclampsia. The urine glycosylation protein marker is selected from any one or more of glycosylation modified SERPINC1 and SERPING1. The invention also discloses application of the reagent for detecting the urine glycosylated protein marker in preparation of a kit for early auxiliary diagnosis of preeclampsia. According to the present invention, the high-throughput screening method is adopted to analyze the glycosylated proteins in the urine of the normal pregnancy pregnant woman and the preeclampsia pregnant woman, such that the glycosylated proteins capable of indicating the preeclampsia disease are screened, and the research basis is provided for the development and the clinical application of the glycosylated protein marker in the urine; besides, in the research method, urine is relatively simple and non-invasive to collect and is easier to obtain, so that the urine is easier to accept by a patient, continuous dynamic monitoring can be performed, changes of markers can be tracked, clinical transformation is easy, and the method is suitable for popularization and application.

The present invention relates to an immune device for discriminating whether a pregnancy or an abnormal pregnancy occurs, and more particularly, to an immune device comprising a novel multi-binding anti-hCG monoclonal antibody capable of jointly recognizing a complete hCG and a beta cf hCG, comprising two detection lines and a quality control line capable of separately detecting the complete hCG and the beta cf hCG contained in a specimen, according to the present invention, it is possible to accurately and quickly distinguish the number of weeks of pregnancy, normal pregnancy, including extrauterine pregnancy, and abnormal pregnancy of a withered egg by numeralizing the ratio of the color development intensity of beta cf hCG (the distribution ratio of beta cf hCG) with respect to the color development intensity of complete hCG and beta cf hCG.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The invention belongs to the technical field of pregnancy risk early warning, and discloses a repeated pregnancy loss risk early warning method and system based on big data, and the method comprises the steps: collecting basic feature data and physiological index data of a research object, marking a normal pregnancy or repeated pregnancy loss mark according to the pregnancy condition, and forming a big database; classifying the data according to basic feature data, and analyzing the association between the physiological indexes and the repeated pregnancy loss risk to form a reference database; obtaining basic feature data of a to-be-evaluated object, and matching target data under the corresponding classification from the reference database; after the physiological indexes of the to-be-evaluated object are obtained, the risk degree is evaluated through comparison with the target data, and finally a risk early warning result is generated. Through an individualized layered evaluation strategy and vectorization analysis of multi-dimensional physiological indexes, the problem of inaccurate early warning caused by adoption of a unified standard in the prior art is solved, and the accuracy of risk early warning is improved.

The present invention relates to an immune device for determining the presence or absence of pregnancy or abnormal pregnancy, and more specifically, to an immune device capable of recognizing both intact hCG and βcf hCG. R This immunological device contains a multi-linked anti-hCG monoclonal antibody, and can separately detect intact hCG and βcf hCG contained in the sample, including two detection lines and a control line.By quantifying the ratio of the color intensity of βcf hCG to the color intensity of intact hCG and βcf hCG (the distribution ratio of βcf hCG), it can accurately and quickly determine the number of weeks of pregnancy, normal pregnancy, ectopic pregnancy, and abnormal pregnancy including blighted oocytes.

The application discloses a serine nano-drug for treating preeclampsia by targeting placental oxidative stress, which can pass through the placental barrier by changing the particle size, thereby increasing the local concentration of serine in the placenta to achieve the purpose of relieving placental oxidative stress and treating preeclampsia. The placental barrier is the barrier between the placental villus tissue and the uterine blood sinus, and is an important basis for maintaining normal pregnancy. However, the placental barrier also hinders the entry of drugs into the placenta, affecting the treatment effect of drugs on placental diseases, such as preeclampsia, fetal intrauterine growth restriction and the like. The nano-drug is prepared by using nano-preparation technology to make raw drugs into particles with a nano scale, and has the advantage of penetrating through the body barrier. The amino acid involved in oxidative stress regulation, serine, is synthesized into nano-serine by using nano technology, so that serine can pass through the placental barrier by changing the particle size of nano-serine, thereby increasing the local concentration of serine in the placenta, and achieving the purpose of treating preeclampsia by reducing placental oxidative stress.

The invention provides an application of judiciyumab in preparation of a medicine for improving the living yield of a patient with recurrent abortion (RSA), and belongs to the field of biological medicine. The Jukoulikumab provided by the invention is a fully humanized monoclonal antibody, can inhibit inflammatory reaction generated by IL-17A activation on the basis of not influencing other immune functions of a body, and has high selectivity. When being applied to mice and RSA patients in the pregnancy period, the Jukoulikumab can improve the immune tolerance of a maternal-fetal interface, obviously improve the embryo survival rate of the RSA mice and the RSA patients, even can reach the same level as normal pregnancy, and does not find embryo or maternal abnormality, so that a new evidence is provided for the pregnant patients to use the Jukoulikumab, and the Jukoulikumab has a wide application prospect. And the safety and the effectiveness of treating the RSA by using the judiciyumab are powerfully proved.

The application discloses a biomarker for predicting unexplained recurrent spontaneous abortion and application thereof, and belongs to the technical field of molecular diagnosis and molecular biology. By comparing serum detection of 45 unexplained recurrent spontaneous abortion patients, it is found that the expression level of miR-142-3p in the serum of the unexplained recurrent spontaneous abortion patients is obviously higher than that of normal pregnant women. Compared with the normal pregnant women, the peripheral blood CD4 + CD25 + Treg cell level of the unexplained recurrent spontaneous abortion patients is significantly increased. By detecting the expression level of miR-142-3p, the unexplained recurrent spontaneous abortion patients can be pre-judged, so that the miR-142-3p can be used as an important index for clinically diagnosing and evaluating unexplained recurrent spontaneous abortion.